474 related articles for article (PubMed ID: 25258345)
21. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
22. Eye tracking identifies biomarkers in α-synucleinopathies versus progressive supranuclear palsy.
Habibi M; Oertel WH; White BJ; Brien DC; Coe BC; Riek HC; Perkins J; Yep R; Itti L; Timmermann L; Best C; Sittig E; Janzen A; Munoz DP
J Neurol; 2022 Sep; 269(9):4920-4938. PubMed ID: 35501501
[TBL] [Abstract][Full Text] [Related]
23. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
[TBL] [Abstract][Full Text] [Related]
24. Alpha-synuclein Levels in the Differential Diagnosis of Lewy Bodies Dementia and Other Neurodegenerative Disorders: A Meta-analysis.
Mavroudis I; Petridis F; Chatzikonstantinou S; Kazis D
Alzheimer Dis Assoc Disord; 2020; 34(3):220-224. PubMed ID: 32341240
[TBL] [Abstract][Full Text] [Related]
25. Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.
Constantinescu R; Andreasson U; Holmberg B; Zetterberg H
Acta Neurol Scand; 2013 Feb; 127(2):e8-12. PubMed ID: 22998191
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
[TBL] [Abstract][Full Text] [Related]
27. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.
Tokuda T; Qureshi MM; Ardah MT; Varghese S; Shehab SA; Kasai T; Ishigami N; Tamaoka A; Nakagawa M; El-Agnaf OM
Neurology; 2010 Nov; 75(20):1766-72. PubMed ID: 20962290
[TBL] [Abstract][Full Text] [Related]
28. New and reliable MRI diagnosis for progressive supranuclear palsy.
Oba H; Yagishita A; Terada H; Barkovich AJ; Kutomi K; Yamauchi T; Furui S; Shimizu T; Uchigata M; Matsumura K; Sonoo M; Sakai M; Takada K; Harasawa A; Takeshita K; Kohtake H; Tanaka H; Suzuki S
Neurology; 2005 Jun; 64(12):2050-5. PubMed ID: 15985570
[TBL] [Abstract][Full Text] [Related]
29. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
[TBL] [Abstract][Full Text] [Related]
30. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
[TBL] [Abstract][Full Text] [Related]
31. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
[TBL] [Abstract][Full Text] [Related]
33. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
Liscic RM; Srulijes K; Gröger A; Maetzler W; Berg D
Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
[TBL] [Abstract][Full Text] [Related]
35. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.
Kanazawa M; Tada M; Onodera O; Takahashi H; Nishizawa M; Shimohata T
Parkinsonism Relat Disord; 2013 Dec; 19(12):1149-51. PubMed ID: 23916652
[TBL] [Abstract][Full Text] [Related]
36. α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders.
Fernandes Gomes B; Farris CM; Ma Y; Concha-Marambio L; Lebovitz R; Nellgård B; Dalla K; Constantinescu J; Constantinescu R; Gobom J; Andreasson U; Zetterberg H; Blennow K
Parkinsonism Relat Disord; 2023 Dec; 117():105807. PubMed ID: 37591709
[TBL] [Abstract][Full Text] [Related]
37. Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow.
Fukui Y; Hishikawa N; Sato K; Yunoki T; Kono S; Matsuzono K; Nakano Y; Ohta Y; Yamashita T; Deguchi K; Abe K
J Neurol Sci; 2015 Oct; 357(1-2):178-82. PubMed ID: 26227830
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
39. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
[TBL] [Abstract][Full Text] [Related]
40. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
